1
|
Kim DR, Martin S, Desai K. The effects of a comparatively higher dose of 1000 mg/kg/d of oral L- or D-arginine on the L-arginine metabolic pathways in male Sprague-Dawley rats. PLoS One 2023; 18:e0289476. [PMID: 37527267 PMCID: PMC10393177 DOI: 10.1371/journal.pone.0289476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 07/19/2023] [Indexed: 08/03/2023] Open
Abstract
Oral L-arginine supplements are popular mainly for their nitric oxide mediated vasodilation, but their physiological impact is not fully known. L-arginine is a substrate of several enzymes including arginase, nitric oxide synthase, arginine decarboxylase, and arginine: glycine amidinotransferase (AGAT). We have published a study on the physiological impact of oral L- and D-arginine at 500 mg/kg/day for 4 wks in male Sprague-Dawley rats. We investigated the effects of oral L-arginine and D-arginine at a higher dose of 1000 mg/kg/d for a longer treatment duration of 16 wks in 9-week-old male Sprague-Dawley rats. We measured the expression and activity of L-arginine metabolizing enzymes, and levels of their metabolites in the plasma and various organs. L-arginine did not affect the levels of L-arginine and L-lysine in the plasma and various organs. L-arginine decreased arginase protein expression in the upper small intestine, and arginase activity in the plasma. It also decreased AGAT protein expression in the liver, and creatinine levels in the urine. L-arginine altered arginine decarboxylase protein expression in the upper small intestine and liver, with increased total polyamines plasma levels. Endothelial nitric oxide synthase protein was increased with D-arginine, the presumed metabolically inert isomer, but not L-arginine. In conclusion, oral L-arginine and D-arginine at a higher dose and longer treatment duration significantly altered various enzymes and metabolites in the arginine metabolic pathways, which differed from alterations produced by a lower dose shorter duration treatment published earlier. Further studies with differing doses and duration would allow for a better understanding of oral L-arginine uses, and evidence based safe and effective dose range and duration.
Collapse
Affiliation(s)
- Dain Raina Kim
- Department of Anatomy, Physiology & Pharmacology, University of Saskatchewan, Saskatoon, SK, Canada
| | - Sarah Martin
- Department of Anatomy, Physiology & Pharmacology, University of Saskatchewan, Saskatoon, SK, Canada
| | - Kaushik Desai
- Department of Anatomy, Physiology & Pharmacology, University of Saskatchewan, Saskatoon, SK, Canada
| |
Collapse
|
2
|
Thompson MA, Martin SA, Hislop BD, Younkin R, Andrews TM, Miller K, June RK, Adams ES. Sex-specific effects of calving season on joint health and biomarkers in Montana ranchers. BMC Musculoskelet Disord 2023; 24:80. [PMID: 36717802 PMCID: PMC9887842 DOI: 10.1186/s12891-022-05979-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Accepted: 11/11/2022] [Indexed: 02/01/2023] Open
Abstract
BACKGROUND Agricultural workers have a higher incidence of osteoarthritis (OA), but the etiology behind this phenomenon is unclear. Calving season, which occurs in mid- to late-winter for ranchers, includes physical conditions that may elevate OA risk. Our primary aim was to determine whether OA biomarkers are elevated at the peak of calving season compared to pre-season, and to compare these data with joint health survey information from the subjects. Our secondary aim was to detect biomarker differences between male and female ranchers. METHODS During collection periods before and during calving season, male (n = 28) and female (n = 10) ranchers completed joint health surveys and provided samples of blood, urine, and saliva for biomarker analysis. Statistical analyses examined associations between mean biomarker levels and survey predictors. Ensemble cluster analysis identified groups having unique biomarker profiles. RESULTS The number of calvings performed by each rancher positively correlated with plasma IL-6, serum hyaluronic acid (HA) and urinary CTX-I. Thiobarbituric acid reactive substances (TBARS), a marker of oxidative stress, was significantly higher during calving season than pre-season and was also correlated with ranchers having more months per year of joint pain. We found evidence of sexual dimorphism in the biomarkers among the ranchers, with leptin being elevated and matrix metalloproteinase-3 diminished in female ranchers. The opposite was detected in males. WOMAC score was positively associated with multiple biomarkers: IL-6, IL-2, HA, leptin, C2C, asymmetric dimethylarginine, and CTX-I. These biomarkers represent enzymatic degradation, inflammation, products of joint destruction, and OA severity. CONCLUSIONS The positive association between number of calvings performed by each rancher (workload) and both inflammatory and joint tissue catabolism biomarkers establishes that calving season is a risk factor for OA in Montana ranchers. Consistent with the literature, we found important sex differences in OA biomarkers, with female ranchers showing elevated leptin, whereas males showed elevated MMP-3.
Collapse
Affiliation(s)
- Matthew A. Thompson
- grid.41891.350000 0001 2156 6108Department of Chemical & Biological Engineering, Montana State University, Bozeman, MT USA
| | - Stephen A. Martin
- grid.41891.350000 0001 2156 6108Center for American Indian and Rural Health Equity, Translational Biomarkers Core Laboratory, Montana State University, Bozeman, MT USA
| | - Brady D. Hislop
- grid.41891.350000 0001 2156 6108Department of Mechanical & Industrial Engineering, Montana State University, PO Box 173800, Bozeman, MT 59717-3800 USA
| | - Roubie Younkin
- grid.41891.350000 0001 2156 6108MSU Extension Office, Montana State University, Bozeman, MT USA
| | - Tara M. Andrews
- grid.41891.350000 0001 2156 6108MSU Extension Office, Montana State University, Bozeman, MT USA
| | - Kaleena Miller
- grid.41891.350000 0001 2156 6108MSU Extension Office, Montana State University, Bozeman, MT USA
| | - Ronald K. June
- grid.41891.350000 0001 2156 6108Department of Mechanical & Industrial Engineering, Montana State University, PO Box 173800, Bozeman, MT 59717-3800 USA
| | - Erik S. Adams
- grid.41891.350000 0001 2156 6108Department of Mechanical & Industrial Engineering, Montana State University, PO Box 173800, Bozeman, MT 59717-3800 USA ,grid.34477.330000000122986657School of Medicine, Montana WWAMI, University of Washington, Seattle, WA USA
| |
Collapse
|
3
|
Guo X, Xing Y, Jin W. Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus. Front Endocrinol (Lausanne) 2023; 14:1183586. [PMID: 37152974 PMCID: PMC10160678 DOI: 10.3389/fendo.2023.1183586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Accepted: 04/11/2023] [Indexed: 05/09/2023] Open
Abstract
Diabetic microangiopathy is a typical and severe problem in diabetics, including diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, and diabetic cardiomyopathy. Patients with type 2 diabetes and diabetic microvascular complications have significantly elevated levels of Asymmetric dimethylarginine (ADMA), which is an endogenous inhibitor of nitric oxide synthase (NOS). ADMA facilitates the occurrence and progression of microvascular complications in type 2 diabetes through its effects on endothelial cell function, oxidative stress damage, inflammation, and fibrosis. This paper reviews the association between ADMA and microvascular complications of diabetes and elucidates the underlying mechanisms by which ADMA contributes to these complications. It provides a new idea and method for the prevention and treatment of microvascular complications in type 2 diabetes.
Collapse
Affiliation(s)
| | | | - Wei Jin
- *Correspondence: Yiqiao Xing, ; Wei Jin,
| |
Collapse
|
4
|
Correia C, Wang QD, Linhardt G, Carlsson LG, Ulfenborg B, Walentinsson A, Rydén-Markinhutha K, Behrendt M, Wikström J, Sartipy P, Jennbacken K, Synnergren J. Unraveling the Metabolic Derangements Occurring in Non-infarcted Areas of Pig Hearts With Chronic Heart Failure. Front Cardiovasc Med 2021; 8:753470. [PMID: 34722683 PMCID: PMC8548620 DOI: 10.3389/fcvm.2021.753470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Accepted: 09/16/2021] [Indexed: 11/13/2022] Open
Abstract
Objective: After myocardial infarction (MI), the non-infarcted left ventricle (LV) ensures appropriate contractile function of the heart. Metabolic disturbance in this region greatly exacerbates post-MI heart failure (HF) pathology. This study aimed to provide a comprehensive understanding of the metabolic derangements occurring in the non-infarcted LV that could trigger cardiovascular deterioration. Methods and Results: We used a pig model that progressed into chronic HF over 3 months following MI induction. Integrated gene and metabolite signatures revealed region-specific perturbations in amino acid- and lipid metabolism, insulin signaling and, oxidative stress response. Remote LV, in particular, showed impaired glutamine and arginine metabolism, altered synthesis of lipids, glucose metabolism disorder, and increased insulin resistance. LPIN1, PPP1R3C, PTPN1, CREM, and NR0B2 were identified as the main effectors in metabolism dysregulation in the remote zone and were found differentially expressed also in the myocardium of patients with ischemic and/or dilated cardiomyopathy. In addition, a simultaneous significant decrease in arginine levels and altered PRCP, PTPN1, and ARF6 expression suggest alterations in vascular function in remote area. Conclusions: This study unravels an array of dysregulated genes and metabolites putatively involved in maladaptive metabolic and vascular remodeling in the non-infarcted myocardium and may contribute to the development of more precise therapies to mitigate progression of chronic HF post-MI.
Collapse
Affiliation(s)
- Cláudia Correia
- Systems Biology Research Center, Translational Bioinformatics Research Group, School of Biosciences, University of Skövde, Skövde, Sweden.,Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Qing-Dong Wang
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Gunilla Linhardt
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Leif G Carlsson
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Benjamin Ulfenborg
- Systems Biology Research Center, Translational Bioinformatics Research Group, School of Biosciences, University of Skövde, Skövde, Sweden
| | - Anna Walentinsson
- Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Katarina Rydén-Markinhutha
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Margareta Behrendt
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Johannes Wikström
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Peter Sartipy
- Systems Biology Research Center, Translational Bioinformatics Research Group, School of Biosciences, University of Skövde, Skövde, Sweden.,Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Karin Jennbacken
- Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Jane Synnergren
- Systems Biology Research Center, Translational Bioinformatics Research Group, School of Biosciences, University of Skövde, Skövde, Sweden
| |
Collapse
|
5
|
OZTAN O, TÜRKSOY VA, DENİZ S, COŞKUN BEYAN A, İRİTAŞ SB, ERCAN M, TUTKUN E. Silicosis and methylated arginines/L-arginines: case-control adapted a cross-sectional design. JOURNAL OF HEALTH SCIENCES AND MEDICINE 2021. [DOI: 10.32322/jhsm.982776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
6
|
Nyborg C, Bonnevie-Svendsen M, Melsom HS, Melau J, Seljeflot I, Hisdal J. Reduced L-Arginine and L-Arginine-ADMA-Ratio, and Increased SDMA after Norseman Xtreme Triathlon. Sports (Basel) 2021; 9:sports9090120. [PMID: 34564325 PMCID: PMC8472968 DOI: 10.3390/sports9090120] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 07/28/2021] [Accepted: 08/26/2021] [Indexed: 12/13/2022] Open
Abstract
Endothelial vasodilatory function is dependent on the NO synthesis from L-arginine by endothelial NO-synthetase (eNOS). eNOS can be inhibited by asymmetric dimethylarginine (ADMA) by competitive inhibition on the binding site, and symmetric dimethylarginine (SDMA) can reduce the L-arginine availability intracellularly through competing for transport over the cellular membrane. To study the NO synthesis after prolonged exercise, we assessed circulatory L-arginine, the L-arginine/ADMA ratio, and SDMA before, after, and on the day after the Norseman Xtreme triathlon, an Ironman distance triathlon. We found significantly reduced levels of L-arginine and the L-arginine/ADMA ratio and increased levels of SDMA after the race (all p < 0.05). L-arginine rose toward baseline levels the day after the race, but ADMA increased beyond baseline levels, and SDMA remained above baseline the day after the race. The reduced levels of L-arginine and the L-arginine/ADMA ratio, and increased SDMA, after the race indicate a state of reduced capability of NO production. Increased levels of ADMA and SDMA, and reduced L-arginine/ADMA ratio, as seen the day after the race, are known risk markers of atherosclerosis and warrant further studies.
Collapse
Affiliation(s)
- Christoffer Nyborg
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway; (M.B.-S.); (H.S.M.); (J.M.); (I.S.); (J.H.)
- Department of Vascular Surgery, Oslo University Hospital, 0424 Oslo, Norway
- Correspondence: ; Tel.: +47-971-76-129
| | - Martin Bonnevie-Svendsen
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway; (M.B.-S.); (H.S.M.); (J.M.); (I.S.); (J.H.)
- Department of Vascular Surgery, Oslo University Hospital, 0424 Oslo, Norway
| | - Helene Støle Melsom
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway; (M.B.-S.); (H.S.M.); (J.M.); (I.S.); (J.H.)
- Department of Vascular Surgery, Oslo University Hospital, 0424 Oslo, Norway
| | - Jørgen Melau
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway; (M.B.-S.); (H.S.M.); (J.M.); (I.S.); (J.H.)
- Department of Vascular Surgery, Oslo University Hospital, 0424 Oslo, Norway
- Department of Prehospital Care, Vestfold Hospital Trust, 3103 Toensberg, Norway
| | - Ingebjørg Seljeflot
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway; (M.B.-S.); (H.S.M.); (J.M.); (I.S.); (J.H.)
- Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, 0424 Oslo, Norway
| | - Jonny Hisdal
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway; (M.B.-S.); (H.S.M.); (J.M.); (I.S.); (J.H.)
- Department of Vascular Surgery, Oslo University Hospital, 0424 Oslo, Norway
| |
Collapse
|
7
|
Arginine and Arginine/ADMA Ratio Predict 90-Day Mortality in Patients with Out-of-Hospital Cardiac Arrest-Results from the Prospective, Observational COMMUNICATE Trial. J Clin Med 2020; 9:jcm9123815. [PMID: 33255752 PMCID: PMC7760544 DOI: 10.3390/jcm9123815] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Revised: 11/08/2020] [Accepted: 11/19/2020] [Indexed: 02/07/2023] Open
Abstract
(1) Background: In patients with shock, the L-arginine nitric oxide pathway is activated, causing an elevation of nitric oxide, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) levels. Whether these metabolites provide prognostic information in patients after out-of-hospital cardiac arrest (OHCA) remains unclear. (2) Methods: We prospectively included OHCA patients, recorded clinical parameters and measured plasma ADMA, SDMA and Arginine levels by liquid chromatography tandem mass spectrometry (LC-MS). The primary endpoint was 90-day mortality. (3) Results: Of 263 patients, 130 (49.4%) died within 90 days after OHCA. Compared to survivors, non-survivors had significantly higher levels of ADMA and lower Arginine and Arginine/ADMA ratios in univariable regression analyses. Arginine levels and Arginine/ADMA ratio were significantly associated with 90-day mortality (OR 0.51 (95%CI 0.34 to 0.76), p < 0.01 and OR 0.40 (95%CI 0.26 to 0.61), p < 0.001, respectively). These associations remained significant in several multivariable models. Arginine/ADMA ratio had the highest predictive value with an area under the curve (AUC) of 0.67 for 90-day mortality. Results for secondary outcomes were similar with significant associations with in-hospital mortality and neurological outcome. (4) Conclusion: Arginine and Arginine/ADMA ratio were independently associated with 90-day mortality and other adverse outcomes in patients after OHCA. Whether therapeutic modification of the L-arginine-nitric oxide pathway has the potential to improve outcome should be evaluated.
Collapse
|
8
|
Grosse GM, Schwedhelm E, Worthmann H, Choe CU. Arginine Derivatives in Cerebrovascular Diseases: Mechanisms and Clinical Implications. Int J Mol Sci 2020; 21:ijms21051798. [PMID: 32150996 PMCID: PMC7084464 DOI: 10.3390/ijms21051798] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Revised: 02/27/2020] [Accepted: 03/01/2020] [Indexed: 02/07/2023] Open
Abstract
The amino acid L-arginine serves as substrate for the nitric oxide synthase which is crucial in vascular function and disease. Derivatives of arginine, such as asymmetric (ADMA) and symmetric dimethylarginine (SDMA), are regarded as markers of endothelial dysfunction and have been implicated in vascular disorders. While there is a variety of studies consolidating ADMA as biomarker of cerebrovascular risk, morbidity and mortality, SDMA is currently emerging as an interesting metabolite with distinct characteristics in ischemic stroke. In contrast to dimethylarginines, homoarginine is inversely associated with adverse events and mortality in cerebrovascular diseases and might constitute a modifiable protective risk factor. This review aims to provide an overview of the current evidence for the pathophysiological role of arginine derivatives in cerebrovascular ischemic diseases. We discuss the complex mechanisms of arginine metabolism in health and disease and its potential clinical implications in diverse aspects of ischemic stroke.
Collapse
Affiliation(s)
- Gerrit M. Grosse
- Department of Neurology, Hannover Medical School, 30625 Hannover, Germany;
- Correspondence:
| | - Edzard Schwedhelm
- Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, 20249 Hamburg, Germany;
- DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung e.V.), partner site Hamburg/Kiel/Lübeck, 20249 Hamburg, Germany
| | - Hans Worthmann
- Department of Neurology, Hannover Medical School, 30625 Hannover, Germany;
| | - Chi-un Choe
- Department of Neurology, University Medical Center Hamburg-Eppendorf, 20249 Hamburg, Germany;
| |
Collapse
|
9
|
Circulating Concentrations of Key Regulators of Nitric Oxide Production in Undernourished Sheep Carrying Single and Multiple Fetuses. Animals (Basel) 2019; 10:ani10010065. [PMID: 31905930 PMCID: PMC7023428 DOI: 10.3390/ani10010065] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2019] [Revised: 12/15/2019] [Accepted: 12/23/2019] [Indexed: 11/17/2022] Open
Abstract
Simple Summary The present study aimed to determine the blood concentrations of L-arginine, asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and L-homoarginine, modulating nitric oxide (NO) synthesis, in single, twin. and triplet pregnancies in ewes undergoing either dietary energy restriction or receiving 100% of their energy requirements. Blood concentrations of L-arginine, of its metabolites. and the ratio between NO synthesis boosters and inhibitors are altered in energy-restricted ewes, these alterations being higher in ewes carrying multiple fetuses. Abstract The aim of this study was to investigate the blood concentrations of L-arginine, asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and L-homoarginine, which are regulators of nitric oxide (NO) synthesis, in single, twin, and triplet pregnancies in ewes undergoing either a dietary energy restriction or receiving 100% of their energy requirements. From day 24 to 100 of pregnancy, the ewes were fed ryegrass hay and two different iso-proteic concentrates fulfilling either 100% of ewes’ energy requirements (control group; n = 30, 14 singleton pregnancies, 12 twin pregnancies, and 4 triplet pregnancies) or only 45% (feed-restricted group; n = 29; 11 singleton pregnancies, 15 twin pregnancies, and 3 triplet pregnancies). Blood samples were collected monthly to measure, by capillary electrophoresis, the circulating concentrations of arginine, ADMA, homoarginine, SDMA, and of other amino acids not involved in NO synthesis to rule out possible direct effects of diet restriction on their concentrations. No differences between groups were observed in the circulating concentrations of most of the amino acids investigated. L-homoarginine increased markedly in both groups during pregnancy (p < 0.001). SDMA (p < 0.01), L-arginine, and ADMA concentrations were higher in feed-restricted ewes than in controls. The L-arginine/ADMA ratio, an indicator of NO production by NOS, decreased towards term without differences between groups. The ADMA/SDMA ratio, an index of the ADMA degrading enzyme activity, was higher in controls than in feed-restricted ewes (p < 0.001). Obtained results show that circulating concentrations of L-arginine, of its metabolites, and the ratio between NO synthesis boosters and inhibitors are altered in energy-restricted ewes, and that these alterations are more marked in ewes carrying multiple fetuses.
Collapse
|
10
|
Sundar UM, Ugusman A, Chua HK, Latip J, Aminuddin A. Piper sarmentosum Promotes Endothelial Nitric Oxide Production by Reducing Asymmetric Dimethylarginine in Tumor Necrosis Factor-α-Induced Human Umbilical Vein Endothelial Cells. Front Pharmacol 2019; 10:1033. [PMID: 31607906 PMCID: PMC6758593 DOI: 10.3389/fphar.2019.01033] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Accepted: 08/14/2019] [Indexed: 12/11/2022] Open
Abstract
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide synthase (eNOS). ADMA is degraded by dimethylarginine dimethylaminohydrolase (DDAH). Elevated levels of ADMA lead to reduction in nitric oxide (NO) production, which is linked to endothelial dysfunction and atherosclerosis. Piper sarmentosum is an herb that has shown stimulation on endothelial NO production by increasing both expression and activity of eNOS. Thus, this study determined whether the positive effect of P. sarmentosum on NO production is related to its modulation on the DDAH-ADMA pathway in cultured human umbilical vein endothelial cells (HUVEC) exposed to tumor necrosis factor-α (TNF-α). HUVEC were divided into four groups: control, treatment with 250 µg/ml of aqueous extract of P. sarmentosum leaves (AEPS), treatment with 30 ng/ml of TNF-α, and concomitant treatment with AEPS and TNF-α for 24 h. After treatments, HUVEC were collected to measure DDAH1 messenger RNA (mRNA) expression using quantitative real-time polymerase chain reaction. DDAH1 protein level was measured using enzyme-linked immunosorbent assay (ELISA), and DDAH enzyme activity was measured using colorimetric assay. ADMA concentration was measured using ELISA, and NO level was measured using Griess assay. Compared to control, TNF-α-treated HUVEC showed reduction in DDAH1 mRNA expression (P < 0.05), DDAH1 protein level (P < 0.01), and DDAH activity (P < 0.05). Treatment with AEPS successfully increased DDAH1 mRNA expression (P < 0.05), DDAH1 protein level (P < 0.01), and DDAH activity (P < 0.05) in TNF-α-treated HUVEC. Treatment with TNF-α caused an increase in ADMA level (P < 0.01) and a decrease in endothelial NO production (P < 0.001). Whereas treatment with AEPS was able to reduce ADMA level (P < 0.01) and restore NO (P < 0.001) in TNF-α-treated HUVEC. The results suggested that AEPS promotes endothelial NO production by stimulating DDAH activity and thus reducing ADMA level in TNF-α-treated HUVEC.
Collapse
Affiliation(s)
- Uma Mahgesswary Sundar
- Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
| | - Azizah Ugusman
- Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
| | - Hui Kien Chua
- Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
| | - Jalifah Latip
- Department of Pharmaceutical Chemistry, School of Chemical Sciences & Food Technology, Faculty of Science and Technology, Universiti Kebangsaan Malaysia, Bangi, Malaysia
| | - Amilia Aminuddin
- Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
| |
Collapse
|
11
|
Ikenaka K, Atsuta N, Maeda Y, Hotta Y, Nakamura R, Kawai K, Yokoi D, Hirakawa A, Taniguchi A, Morita M, Mizoguchi K, Mochizuki H, Kimura K, Katsuno M, Sobue G. Increase of arginine dimethylation correlates with the progression and prognosis of ALS. Neurology 2019; 92:e1868-e1877. [PMID: 30867270 DOI: 10.1212/wnl.0000000000007311] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Accepted: 12/17/2018] [Indexed: 12/13/2022] Open
Abstract
OBJECTIVE To investigate whether arginine methylation is altered in patients with amyotrophic lateral sclerosis (ALS) and how it affects disease severity, progression, and prognosis. METHODS We compared the immunoreactivity of protein arginine methyltransferase 1 (PRMT1) and its products, asymmetric dimethylated proteins (ASYM), in postmortem spinal cord. We also measured the concentrations of total l-arginine and methylated arginine residues, including asymmetric dimethyl l-arginine (ADMA), symmetric dimethyl arginine, and monomethyl arginine, in CSF samples from 52 patients with ALS using liquid chromatography-tandem mass spectrometry, and we examined their relationship with the progression and prognosis of ALS. RESULTS The immunoreactivity of both PRMT1 (p < 0.0001) and ASYM (p = 0.005) was increased in patients with ALS. The concentration of ADMA in CSF was substantially higher in patients with ALS than in disease controls. The ADMA/l-arginine ratio was correlated with the change of decline in the ALS Functional Rating Scale at 12 months after the time of measurement (r = 0.406, p = 0.010). A Cox proportional hazards model showed that the ADMA/l-arginine ratio was an independent predictor for overall survival. Moreover, a high ADMA/l-arginine ratio predicted poor prognosis, even in a group with normal percentage forced vital capacity. CONCLUSION There was an enhancement of arginine dimethylation in patients with ALS, and the ADMA/l-arginine ratio predicted disease progression and prognosis in such patients.
Collapse
Affiliation(s)
- Kensuke Ikenaka
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan
| | - Naoki Atsuta
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan
| | - Yasuhiro Maeda
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan
| | - Yuji Hotta
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan
| | - Ryoichi Nakamura
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan
| | - Kaori Kawai
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan
| | - Daichi Yokoi
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan
| | - Akihiro Hirakawa
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan
| | - Akira Taniguchi
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan
| | - Mitsuya Morita
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan
| | - Kouichi Mizoguchi
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan
| | - Hideki Mochizuki
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan
| | - Kazunori Kimura
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan
| | - Masahisa Katsuno
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan
| | - Gen Sobue
- From the Department of Neurology (K.I., N.A., R.N., K. Kawai, D.Y., M.K., G.S.), Nagoya University Graduate School of Medicine; Department of Neurology (K.I., H.M.), Osaka University Graduate School of Medicine, Suita; Department of Hospital Pharmacy (Y.M., Y.H., K. Kimura), Nagoya City University Graduate School of Pharmaceutical Sciences; Department of Biostatistics and Bioinformatics (A.H.), University of Tokyo; Department of Neurology (A.T.), Mie University Graduate School of Medicine, Tsu; Department of Neurology (M.M.), Jichi Medical University, Shimotsuke, Tochigi; National Hospital Organization, Shizuoka Medical Center (K.M.); and Brain and Mind Research Center (G.S.), Nagoya University, Aichi, Japan.
| |
Collapse
|
12
|
Jarquin Campos A, Risch L, Baumann M, Purde MT, Neuber S, Renz H, Mosimann B, Raio L, Mohaupt M, Surbek D, Risch M. Shrunken pore syndrome, preeclampsia, and markers of NO metabolism in pregnant women during the first trimester. Scandinavian Journal of Clinical and Laboratory Investigation 2019; 79:91-98. [DOI: 10.1080/00365513.2019.1568150] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Araceli Jarquin Campos
- Private University of the Principality of Liechtenstein, Triesen, Liechtenstein
- Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein
| | - Lorenz Risch
- Private University of the Principality of Liechtenstein, Triesen, Liechtenstein
- Labormedizinisches Zentrum Dr. Risch, Vaduz, Liechtenstein
- University Institut of Clinical Chemistry, University of Bern, Bern, Switzerland
| | - Marc Baumann
- Department of Obstetrics and Gynecology, Inselspital, University of Bern, Bern, Switzerland
| | | | | | - Harald Renz
- Institute of Laboratory Medicine, Philipps University Marburg, Marburg, Germany
| | - Beatrice Mosimann
- Department of Obstetrics and Gynecology, Inselspital, University of Bern, Bern, Switzerland
| | - Luigi Raio
- Department of Obstetrics and Gynecology, Inselspital, University of Bern, Bern, Switzerland
| | - Markus Mohaupt
- Klinik und Poliklinik für Innere Medizin, Bern, Switzerland
- School of Medicine, Division of Child Health, Obstetrics and Gynaecology, University of Nottingham, Nottingham, UK
| | - Daniel Surbek
- Department of Obstetrics and Gynecology, Inselspital, University of Bern, Bern, Switzerland
| | - Martin Risch
- Kantonsspital Graubünden, Zentrallabor, Chur, Switzerland
| |
Collapse
|
13
|
Adingupu DD, Göpel SO, Grönros J, Behrendt M, Sotak M, Miliotis T, Dahlqvist U, Gan LM, Jönsson-Rylander AC. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob -/- mice. Cardiovasc Diabetol 2019; 18:16. [PMID: 30732594 PMCID: PMC6366096 DOI: 10.1186/s12933-019-0820-6] [Citation(s) in RCA: 106] [Impact Index Per Article: 21.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Accepted: 01/28/2019] [Indexed: 12/15/2022] Open
Abstract
Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first class of anti-diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In clinical studies it has been shown that SGLT2i’s promote a general shift to fasting state metabolism characterized by reduced body weight and blood glucose, increase in glucagon/insulin ratio and modest increase in blood ketone levels. Therefore, we investigated the connection between metabolic changes and cardiovascular function in the ob/ob−/− mice; a rodent model of early diabetes with specific focus on coronary microvascular function. Due to leptin deficiency these mice develop metabolic syndrome/diabetes and hepatic steatosis. They also develop cardiac contractile and microvascular dysfunction and are thus a promising model for translational studies of cardiometabolic diseases. We investigated whether this mouse model responded in a human-like manner to empagliflozin treatment in terms of metabolic parameters and tested the hypothesis that it could exert direct effects on coronary microvascular function and contractile performance. Methods Lean, ob/ob−/− untreated and ob/ob−/− treated with SGLT2i were followed for 10 weeks. Coronary flow velocity reserve (CFVR) and fractional area change (FAC) were monitored with non-invasive Doppler ultrasound imaging. Food intake, urinary glucose excursion and glucose control via HbA1c measurements were followed throughout the study. Liver steatosis was assessed by histology and metabolic parameters determined at the end of the study. Results Sodium-glucose cotransporter 2 inhibitors treatment of ob/ob−/− animals resulted in a switch to a more catabolic state as observed in clinical studies: blood cholesterol and HbA1c were decreased whereas glucagon/insulin ratio and ketone levels were increased. SGLT2i treatment reduced liver triglyceride, steatosis and alanine aminotransferase, an indicator for liver dysfunction. l-Arginine/ADMA ratio, a marker for endothelial function was increased. SGLT2i treatment improved both cardiac contractile function and coronary microvascular function as indicated by improvement of FAC and CFVR, respectively. Conclusions Sodium-glucose cotransporter 2 inhibitors treatment of ob/ob−/− mice mimics major clinical findings regarding metabolism and cardiovascular improvements and is thus a useful translational model. We demonstrate that SGLT2 inhibition improves coronary microvascular function and contractile performance, two measures with strong predictive values in humans for CV outcome, alongside with the known metabolic changes in a preclinical model for prediabetes and heart failure.
Collapse
Affiliation(s)
- Damilola D Adingupu
- Bioscience, Cardiovascular, Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal, 431 83, Gothenburg, Sweden
| | - Sven O Göpel
- Bioscience, Cardiovascular, Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal, 431 83, Gothenburg, Sweden.
| | - Julia Grönros
- Bioscience, Cardiovascular, Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal, 431 83, Gothenburg, Sweden
| | - Margareta Behrendt
- Bioscience, Cardiovascular, Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal, 431 83, Gothenburg, Sweden
| | - Matus Sotak
- Bioscience, Cardiovascular, Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal, 431 83, Gothenburg, Sweden
| | - Tasso Miliotis
- Translational Science, Cardiovascular, Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca Gothenburg, Gothenburg, Sweden
| | - Ulrika Dahlqvist
- Bioscience, Cardiovascular, Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal, 431 83, Gothenburg, Sweden
| | - Li-Ming Gan
- Early Clinical Development, Cardiovascular, Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca Gothenburg, Gothenburg, Sweden.,Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.,Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Ann-Cathrine Jönsson-Rylander
- Bioscience, Cardiovascular, Renal and Metabolic Diseases, IMED Biotech Unit, AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal, 431 83, Gothenburg, Sweden
| |
Collapse
|
14
|
Sozański T, Kucharska AZ, Wiśniewski J, Fleszar MG, Rapak A, Gomułkiewicz A, Dzięgiel P, Magdalan J, Nowak B, Szumny D, Matuszewska A, Piórecki N, Szeląg A, Trocha M. The iridoid loganic acid and anthocyanins from the cornelian cherry (Cornus mas L.) fruit increase the plasma l-arginine/ADMA ratio and decrease levels of ADMA in rabbits fed a high-cholesterol diet. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2019; 52:1-11. [PMID: 30599888 DOI: 10.1016/j.phymed.2018.09.175] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Revised: 08/09/2018] [Accepted: 09/17/2018] [Indexed: 06/09/2023]
Abstract
BACKGROUND Although fruit and vegetable-rich diets have beneficial effects on cardiovascular diseases, we have little knowledge of the impact of fruits and their constituents, iridoids and anthocyanins, on the l-arginine-ADMA-DDAH pathway. Our previous study demonstrated the modulation of those factors by the oral administration of the cornelian cherry fruit. HYPOTHESIS/PURPOSE We have assessed the effects of the oral administration of two main constituents isolated from the cornelian cherry fruit, iridoid loganic acid and anthocyanins, on l-arginine, its derivatives (ADMA, SDMA), metabolites (DMA, l-citrulline), and the hepatic DDAH activity and its isoform expression in rabbits fed a high-cholesterol diet. We have also analyzed eNOS expression in the thoracic aorta as well as the redox status in blood. STUDY DESIGN In the present study, we used an animal model of diet induced atherosclerosis. For 60 days, white New Zealand rabbits were fed a standard diet, a 1% cholesterol enriched diet, or concomitantly with the investigated substances. l-arginine, ADMA, SDMA, DMA, and l-citrulline were assessed using the LC-MS/MS method. DDAH activity and redox parameters were analyzed spectrophotometrically. DDAH1 and DDAH2 isoform expressions were assessed by western blotting, mRNA expression of eNOS was quantified by real-time PCR. RESULTS We demonstrated that the administration of loganic acid (20 mg/kg b.w.), and to a lesser extent of anthocyanins (10 mg/kg b.w.), caused an increase in the l-arginine level and the l-arginine/ADMA ratio. Also, both substances decreased ADMA, DMA, and l-citrulline, but not SDMA levels. Anthocyanins, but not loganic acid, enhanced the activity of DDAH in the liver. Anthocyanins also significantly enhanced both DDAH1 and DDAH2 expression, while loganic acid to a lesser extent enhanced DDAH1 but not DDAH2 expression. Both loganic acid and anthocyanins pronouncedly increased mRNA expression of eNOS in thoracic aortas. Both loganic acid and anthocyanins reversed the blood glutathione level depleted by dietary cholesterol. Cholesterol feeding decreased the blood GPx level, and the change was not reversed by anthocyanins or loganic acid. We did not observe any significant differences in the blood levels of MDA or SOD among the groups. CONCLUSION Iridoids and anthocyanins may modulate the l-arginine-ADMA pathway in subjects fed a high-cholesterol diet.
Collapse
Affiliation(s)
- Tomasz Sozański
- Department of Pharmacology, Wroclaw Medical University, Jana Mikulicza-Radeckiego 2, Wrocław 50-345, Poland.
| | - Alicja Z Kucharska
- Department of Fruit, Vegetable and Plant Nutraceutical Technology, Wroclaw University of Environmental and Life Sciences, Chełmońskiego 37, Wrocław 51-630, Poland
| | - Jerzy Wiśniewski
- Department of Medical Biochemistry, Wroclaw Medical University, Chałubińskiego 10, Wrocław 50-368, Poland
| | - Mariusz G Fleszar
- Department of Medical Biochemistry, Wroclaw Medical University, Chałubińskiego 10, Wrocław 50-368, Poland
| | - Andrzej Rapak
- Laboratory of Tumor Molecular Immunobiology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, Wrocław 53-114, Poland
| | - Agnieszka Gomułkiewicz
- Department of Human Morphology and Embryology, Division of Histology and Embryology, Wroclaw Medical University, Chałubińskiego 6a, Wrocław 50-368, Poland
| | - Piotr Dzięgiel
- Department of Human Morphology and Embryology, Division of Histology and Embryology, Wroclaw Medical University, Chałubińskiego 6a, Wrocław 50-368, Poland; Department of Physiotherapy, University School of Physical Education, I.J. Paderewskiego 35, Wroclaw 51-612, Poland
| | - Jan Magdalan
- Department of Pharmacology, Wroclaw Medical University, Jana Mikulicza-Radeckiego 2, Wrocław 50-345, Poland
| | - Beata Nowak
- Department of Pharmacology, Wroclaw Medical University, Jana Mikulicza-Radeckiego 2, Wrocław 50-345, Poland
| | - Dorota Szumny
- Department of Pharmacology, Wroclaw Medical University, Jana Mikulicza-Radeckiego 2, Wrocław 50-345, Poland
| | - Agnieszka Matuszewska
- Department of Pharmacology, Wroclaw Medical University, Jana Mikulicza-Radeckiego 2, Wrocław 50-345, Poland
| | - Narcyz Piórecki
- Bolestraszyce Arboretum and Institute of Physiography, Przemyśl 37-700, Poland; Department of Tourism and Recreation, University of Rzeszow, Towarnickiego 3, Rzeszów 35-959, Poland
| | - Adam Szeląg
- Department of Pharmacology, Wroclaw Medical University, Jana Mikulicza-Radeckiego 2, Wrocław 50-345, Poland
| | - Małgorzata Trocha
- Department of Pharmacology, Wroclaw Medical University, Jana Mikulicza-Radeckiego 2, Wrocław 50-345, Poland
| |
Collapse
|
15
|
Brinkmann SJH, Wörner EA, van Leeuwen PAM. Strict glucose control and artificial regulation of the NO-ADMA-DDAH system in order to prevent endothelial dysfunction. J Physiol 2017; 594:2775-6. [PMID: 27246541 DOI: 10.1113/jp272183] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2016] [Accepted: 03/11/2016] [Indexed: 11/08/2022] Open
Affiliation(s)
| | - E A Wörner
- Department of Surgery, VU University Medical Center, Amsterdam, The Netherlands
| | | |
Collapse
|
16
|
Decroix L, Tonoli C, Soares DD, Descat A, Drittij-Reijnders MJ, Weseler AR, Bast A, Stahl W, Heyman E, Meeusen R. Acute cocoa Flavanols intake has minimal effects on exercise-induced oxidative stress and nitric oxide production in healthy cyclists: a randomized controlled trial. J Int Soc Sports Nutr 2017; 14:28. [PMID: 28811749 PMCID: PMC5553857 DOI: 10.1186/s12970-017-0186-7] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2016] [Accepted: 08/06/2017] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Cocoa flavanols (CF) can stimulate vasodilation by improved nitric oxide (NO) synthesis and have antioxidant and anti-inflammatory capacities. This study aimed to examine whether acute CF intake can affect exercise-induced changes in antioxidant capacity, oxidative stress, inflammation and NO production, as well as exercise performance and recovery in well-trained cyclists. METHODS Twelve well-trained male cyclists (mean ± SD age, VO2max: 30 ± 3 years, 63.0 ± 3.5 ml/kg/min) participated in this randomized, double-blind, cross over study. On 2 separate occasions, subjects performed two 30-min time trials 1.5 (TT1) and 3 (TT2) hours after CF (900 mg CF) or placebo (PL, 13 mg CF) intake, interposed by passive rest. Lactate, glucose, heartrate, rating of perceived exertion (RPE) and power output were measured during the TTs. Blood was drawn at baseline, before and after each TT and analyzed for epicatechin serum concentrations, trolox equivalent antioxidative capacity (TEAC), uric acid (UA), malonaldehyde (MDA), L-arginine/ADMA, citrulline, interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)-α plasma concentrations. Relative changes in blood markers and pacing strategy during TT were analysed by repeated measured ANOVA. TT performance was compared between PL and CF by paired t-test. RESULTS Epicatechin concentrations were increased by CF intake. Exercise-induced increase in TEAC/UA was improved by CF intake (F(1) = 5.57; p = .038) (post-TT1: PL: 113.34 ± 3.9%, CF: 117.64 ± 3.96%, post-TT2: PL: 108.59 ± 3.95%, CF: 123.72 ± 7.4% to baseline), while exercise-induced increases in MDA, IL-1 and IL-6 were not affected by CF intake. TNF-α was unaltered by exercise and by CF. Exercise-induced decreases in L-arginine/ADMA and increases in citrulline were not affected by CF intake. TT1 and TT2 performance and exercise-induced physiological changes were unaffected by CF intake. CONCLUSION Acute CF intake increased total antioxidant capacity in rest and during exercise, but did not affect exercise-induced lipid peroxidation, inflammation, nor NO production in healthy athletes. Acute CF intake did not improve TT performance and recovery. TRIAL REGISTRATION ISRCTN32875, 21-11-2016, retrospectively registered.
Collapse
Affiliation(s)
- Lieselot Decroix
- Human Physiology Research Group, Faculty of Physical Education and Physical Therapy, Vrije Universiteit Brussel, Brussels, Belgium.,Department of Physical Activity, Muscle and Health, Faculty of Sport Sciences and Physical Education, Université de Lille, Lille, France
| | - Cajsa Tonoli
- Human Physiology Research Group, Faculty of Physical Education and Physical Therapy, Vrije Universiteit Brussel, Brussels, Belgium.,Department of Physical Activity, Muscle and Health, Faculty of Sport Sciences and Physical Education, Université de Lille, Lille, France.,Department Rehabilitation sciences and kinesitherapy, Faculty of Physical Education and Physical Therapy, Universiteit Gent, Ghent, Belgium
| | - Danusa Dias Soares
- Department of Physical Education, University of Minas Gerais, Belo Horizonte, Brazil
| | - Amandine Descat
- Center of measurements and analysis (CMA), Facultyof Pharmaceutical Sciences, Université de Lille, Lille, France
| | | | - Antje R Weseler
- Department of Pharmacology and Toxicology, Maastricht University, Maastricht, the Netherlands
| | - Aalt Bast
- Department of Pharmacology and Toxicology, Maastricht University, Maastricht, the Netherlands
| | - Wilhelm Stahl
- Institute of Biochemistry and Molecular Biology I, Faculty of Medicine, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany
| | - Elsa Heyman
- Department of Physical Activity, Muscle and Health, Faculty of Sport Sciences and Physical Education, Université de Lille, Lille, France
| | - Romain Meeusen
- Human Physiology Research Group, Faculty of Physical Education and Physical Therapy, Vrije Universiteit Brussel, Brussels, Belgium
| |
Collapse
|
17
|
Sozański T, Kucharska AZ, Szumny D, Magdalan J, Merwid-Ląd A, Nowak B, Piórecki N, Dzimira S, Jodkowska A, Szeląg A, Trocha M. Cornelian cherry consumption increases the l -arginine/ADMA ratio, lowers ADMA and SDMA levels in the plasma, and enhances the aorta glutathione level in rabbits fed a high-cholesterol diet. J Funct Foods 2017. [DOI: 10.1016/j.jff.2017.04.028] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|